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Introduction
This white paper provides clinicians with practical advice related to
Clostridioides difficile in neonatal intensive care unit (NICU)
patients. Clostridioides difficile infection (CDI) is among the most
prevalent and important healthcare-associated infections (HAIs)
affecting children,1,2 but reports of CDI in infants< 12 months of
age are rare, perhaps because of a relative resistance to the effects of
C. difficile toxins or other protective factors in the intestinal
environment of infants.3 Additionally, high colonization rates in
infants (~35%) make interpretation of positive C. difficile tests in
NICU patients uniquely challenging. For these reasons, the authors
do not recommend routine testing for C. difficile in NICU patients;
NICU patients should be evaluated for other more common causes
of diarrhea. Few data exist in the published literature about pre-
venting C. difficile in the NICU in endemic settings.
Intended use
The SHEA intends this document to serve as a companion to the
Centers for Disease Control and Prevention (CDC) Healthcare
Infection Control Practices Advisory Committee (HICPAC)
“Clostridioides difficile in Neonatal Intensive Care Unit Patients:
A Systematic Review,” to provide practical, expert opinion-based
answers to frequently asked questions on C. difficile detection and
prevention in the NICU. These questions are not adequately
addressed in the published literature to meet Grading of
Recommendations Assessment, Development and Evaluation
(GRADE) standards4 and therefore were not included in the
HICPAC systematic review.
No guideline, expert guidance, or white paper can anticipate
all situations, and this document is not meant to be a substitute
for individual judgment by qualified professionals.
Methods
This document was developed by a writing panel of pediatric and
pathogen-specific experts who collaborated with members of the
HICPAC systematic review writing panel and the SHEA Pediatric
Leadership Council to identify questions that should be addres-
sed. Unlike the SHEA expert guidance format, this document is
not based on a systematic literature search; instead, for the
selected topic, the authors provide practical approaches in
question-and-answer format based on expert opinion and con-
sensus within the context of the HICPAC systematic review.
The SHEA Guidelines Committee and the SHEA Publications
Committee reviewed this document, and the SHEA Board of
Trustees endorsed it. The paper has also been endorsed by the
American Hospital Association (AHA), The Joint Commission,
The Pediatric Infectious Diseases Society (PIDS), the Association
for Professionals in Infection Control and Epidemiology (APIC),
the Infectious Diseases Society of America (IDSA), and the
National Association of Neonatal Nurses (NANN).
Authors
The authors are current and past members of the SHEA Guidelines
Committee and the SHEA Pediatric Leadership Council, who serve
as volunteers. All authors are involved at their respective institutions
in the development of policies pertaining to pediatric infection
prevention, either directly or in an advisory role.
The NICU Advisory Panel, which provided oversight and review
of the paper, is composed of representatives from the Society for
Healthcare Epidemiology of America (SHEA), the American
Academy of Pediatrics (AAP), the Association for Professionals in
Infection Control and Epidemiology (APIC), the Infectious Diseases
Society of America (IDSA), the National Association of Neonatal
Nurses (NANN), the Pediatric Infectious Diseases Society (PIDS),
and The Joint Commission.
Practical approaches: questions and answers
Question: When should clinicians test a NICU patient for CDI?
Answer:
∙ The authors advise against routine testing for CDI in NICU
patients because of the high prevalence of asymptomatic
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carriage of toxigenic C. difficile in infants< 12 months of
age. When C. difficile or its toxins are detected in the stool of
an infant, clinicians may not be able to determine with
certainty that a positive result represents CDI.
∙ Clinicians should test NICU patients for CDI only if there is
evidence of pseudomembranous colitis or if the patient has
clinically significant diarrhea and other noninfectious and
infectious causes of diarrhea have been excluded.
In general, a case of CDI is defined as the presence of clinically
significant diarrhea or toxic megacolon in conjunction with either a
positive test for toxigenic C. difficile or its toxins in the stool, or
evidence of pseudomembranous colitis by endoscopy, surgery, or
histopathology. For adults, the IDSA/SHEA clinical practice
guideline for C. difficile infection recommends patients with unex-
plained and new-onset ≥3 unformed stools in 24 hours as the
preferred target population for testing for CDI.5 Testing patients
without clinically significant diarrhea will decrease the positive
predictive value of a positive test for CDI,6 but no universally
accepted or validated definition of clinically significant diarrhea
exists for infants. In addition, infants< 12 months of age have a
high rate of colonization with C. difficile,7–9 and even when diarrhea
is present, it is difficult to be certain that a positive test result
represents CDI (as opposed to the detection of colonization in a
patient in whom there may be alternative etiologies of diarrhea). For
these reasons, and because of the lack of a clear association between
positive tests and true clinical disease in infants, the IDSA/SHEA
guideline recommends that testing for CDI should never be routi-
nely recommended in endemic circumstances for neonates or
infants< 12 months of age who have diarrhea.5
Question: Before or concurrent with C. difficile testing, which
gastrointestinal pathogens should clinicians test for in a NICU
patient who develops diarrhea?
Answer: Before testing a NICU patient with suspected infectious
diarrhea for CDI, clinicians should
∙ Perform a thorough investigation for potential noninfec-
tious causes of diarrhea in NICU patients.
∙ Test the stool for norovirus, rotavirus, adenovirus, and
enterovirus.
∙ Consider bacterial stool cultures (eg, Salmonella, Shigella,
Campylobacter, Yersinia, and Shiga-toxin–producing E. coli)
for infants who were admitted to the NICU from the
community, or who have a known or suspected exposure to
bacterial enteritis.
Approximately 35% of neonates are colonized with C. difficile,
and toxigenic strains can persist for months.3,8,10 In the absence of a
clear association with infant disease, the authors do not advise
testing for CDI unless other possibilities have been excluded.11
Because diarrhea in a NICU patient is often noninfectious,
before testing for CDI, clinicians should perform a thorough
examination and review of the infant’s medical history, feeding,
and medications to exclude other more likely causes of diarrhea
(eg, feeding intolerance or milk protein allergy, malabsorption,
opioid withdrawal, etc).
Cohort studies evaluating the prevalence of viruses in the stool of
NICU patients have shown low endemic rates of gastrointestinal
pathogens.12 Norovirus, rotavirus, enteroviruses, and adenoviruses
are common pathogens and have been reported to cause infections
and outbreaks in preterm infants.13–17 Therefore, the authors sug-
gest testing for these viruses in an infant with suspected infectious
diarrhea if providers have access to a laboratory with those cap-
abilities. The presence of C. difficile toxin can create cytopathic
effects in tissue culture and can lead to false-positive results for stool
viral culture.18 Because C. difficile toxin would be expected to be
present due to colonization in a substantial proportion of infants,
the authors suggest that facilities use polymerase chain reaction
(PCR) assays (a sensitive and rapid testing method for these viruses)
as a preferred modality for viral testing. An outbreak may warrant a
broader investigation of potential pathogens.
Bacterial pathogens such as Salmonella19 and Escherichia coli20–22
have been linked to NICU outbreaks. Routinely testing NICU
patients with suspected infectious diarrhea for bacterial pathogens is
unlikely to have a high yield, but in the setting of a community or
hospital outbreak, symptomatic family or healthcare contacts, recent
admission from the community, or concern for bloody or muco-
purulent diarrhea, such testing may be warranted. Some institutions
use multiplex PCR assays to identify gastrointestinal pathogens, and
some of these panels include C. difficile. If a multiplex panel is used
to test a NICU patient for other pathogens, clinicians should be
aware that C. difficilemay be detected with high frequency in this age
group. A positive result may reflect colonization rather than infec-
tion and may not warrant treatment.23 For this reason, some facil-
ities suppress the C. difficile result on these panels and require a
separate dedicated test if CDI is a concern.
Question: What are the best methods for testing for CDI in
NICU patients?
Answer:
∙ If clinicians consider testing a NICU patient for CDI, the
authors advise using a stool toxin test as part of a multistep
algorithm rather than using a nucleic acid amplification test
(NAAT) alone.
∙ The facility should not use toxin enzyme immunoassay
(EIA) as a stand-alone test to diagnose CDI.
∙ Repeat testing after a negative result and tests of cure are not
recommended.
Because CDI is a toxin-mediated disease, any testing strategy
must include detection of either toxin or a toxigenic organism.
1. NAATs, primarily polymerase chain reaction testing for the
genes for toxins A and B,
∙ Are more sensitive for C. difficile detection than toxin
EIA tests, but
∙ Their positive predictive value can be low,24 particu-
larly when the prevalence of colonization is high (as is
true for infants).
2. Toxin EIA testing
∙ In addition to having lower sensitivity than NAAT, may
also be prone to false-positive results in children.25
∙ Is not recommended as a stand-alone approach to
diagnosis.
3. Glutamate dehydrogenase (GDH) immunoassays
∙ Detect a highly conserved antigen present in all C.
difficile isolates.
∙ Can be used as a component of 2- or 3-step algorithms
with subsequent toxin testing, in which a negative
toxin EIA result is sometimes arbitrated by NAAT as
outlined in the IDSA/SHEA guideline.5
1150 Thomas J. Sandora et al
In a population with a low pretest probability of disease, such
as NICU patients, the authors believe that it is most appropriate
to choose a diagnostic approach that includes a toxin test to
increase the specificity of the result. Although some experts have
recommended that toxigenic culture be included as part of CDI
testing for infants,26 it is impractical for most clinical labs to
perform culture and this approach is rarely used in practice.
Repeat testing after an initial negative result is associated with
higher rates of false-positive results and unnecessary antibiotic
therapy.27–30 Similarly, “test of cure” specimens are not useful.
C. difficile toxin can persist in stool for up to a month after reso-
lution of diarrhea following treatment. Continued detection of toxin
after disease resolution may lead to false-positive test results,
unnecessary therapy, and prolonged contact precautions.31,32
Question: What is the preferred hand hygiene agent when caring
for NICU patients who test positive for C. difficile?
Answer:
1. In a nonoutbreak setting, there is no consensus on the
optimal approach to hand hygiene when caring for a
patient with CDI. Based on a hospital’s assessment of risk,
any of the following options could be considered:
∙ Standard hand hygiene using alcohol-based hand rub
(ABHR) for room entry and exit
∙ Soap and water hand hygiene for room exit only, with
ABHR for room entry and when needed between tasks
for a single patient unless hands are visibly soiled
∙ Soap and water preferred over ABHR for room entry
and exit
2. Soap and water are recommended for hand hygiene during
a C. difficile outbreak or in hyperendemic settings.
3. The facility must consider sink accessibility when making
recommendations for soap-and-water hand hygiene.
Barriers to hand hygiene will have the effect of decreasing
hand hygiene compliance, so hand hygiene should be made as
convenient as possible. Gloves are effective at preventing con-
tamination of the hands with C. difficile, but they are not a
substitute for effective hand hygiene.31 Patients may be infected
or colonized with >1 pathogen, and ABHR effectively interrupts
transmission of most other organisms.33 It is reasonable to use
ABHR before patient contact and within the patient’s area when
moving from dirty to clean (eg, after a dressing change or diaper
change, before starting a feeding).
Although alcohol is not sporicidal, handwashing with soap
and water is not a perfect option, as handwashing may
remove< 1 log10 of C. difficile spores.
31 The potential advantage
of soap and water for C. difficile spores must be weighed against
the potential disadvantage of lower hand hygiene compliance
when soap and water use is recommended. Hospitals should
make recommendations according to their assessment of risk, as
well as the availability of infrastructure (sinks and ABHR) to
support those recommendations.
Question: What is the appropriate type and duration of isolation
for an infant with a positive C. difficile test?
Recommendations:
∙ Infants with diarrhea and a positive C. difficile test should be
placed on contact precautions. Infants without diarrhea who
have tested positive for C. difficile do not require contact
precautions.
∙ Contact precautions can be discontinued 48 hours after
diarrhea has resolved. At that time, consideration can be
given to moving the patient to a new incubator and/or a
new room.
Clostridioides difficile infections are transmitted from infected
patients to other patients, either directly or indirectly, through the
environment. Hands of healthcare workers in conjunction with
environmental contamination are recognized sources of trans-
mission.34,35 Healthcare worker hand contamination increases
as the rate of environmental contamination increases. Environ-
mental contamination is higher in rooms of patients with
C. difficile-associated diarrhea than in rooms of patients who do
not have diarrhea.36 Patients with asymptomatic C. difficile
colonization shed spores, but generally they shed fewer spores and
cause less contamination than symptomatic patients.31 Thus,
contact precautions are important to preventing transmission
from patients with CDI and should be used until 48 hours after
resolution of diarrhea. Although prolongation of contact pre-
cautions until discharge is a strategy that can be adopted for older
patients when CDI rates remain high, extending this practice to
NICU patients is not recommended for the following reasons:
1. Determining true CDI rates in the NICU is difficult
because testing is not recommended and positive results
most likely reflect colonization.
2. Prolonging contact precautions until discharge could result
in extended isolation for premature infants who are
expected to remain hospitalized for long durations.
Although emerging data suggest that asymptomatic carriers
may also play a role in transmission, current guidelines do
not recommend using contact precautions for colonized
patients without diarrhea.5
Bacterial burden in stool of patients with CDI decreases with
appropriate treatment, but it does not correlate with the amount
of diarrhea.37 Given the risk of persistent contamination of
environmental surfaces in a patient’s room (and inside and
around an incubator), consideration should be given to moving
the patient to a new room and/or changing the incubator or
warmer after diarrhea has resolved to further decrease the risk of
transmission, although no specific data addressing the effective-
ness of this strategy are available.
Question: What is the appropriate cleaning and disinfection
strategy for C. difficile in the NICU?
Answer:
∙ In endemic settings, standard daily cleaning is appropriate.
∙ Bleach or another product with an Environmental Protec-
tion Agency–approved claim for C. difficile sporicidal
activity should be considered for disinfecting the environ-
ment during CDI outbreaks or in hyperendemic settings.
∙ For patients whose CDI has resolved but whose continued
hospitalization is required, consider moving the patient to a
new room once diarrhea has resolved.
∙ Incubators may be thought of similarly to the patient’s room:
° In endemic settings, standard cleaning and processing of
an incubator should occur before it is used for the next
patient.
° Consider moving the patient to a clean incubator when
diarrhea has resolved.
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∙ Develop a strong communication plan with environmental
services to identify rooms requiring cleaning with a
sporicidal disinfectant.
Data are conflicting as to whether inactivation of spores is
necessary to prevent C. difficile transmission in the endemic
setting.31 The decision to use a sporicidal disinfectant (eg, bleach)
for C. difficile patient rooms in a nonoutbreak setting should take
into consideration workflow and communication with environ-
mental services. A system will be needed to alert environmental
services staff to rooms requiring sporicidal disinfection.
No studies have examined incubators as potential reservoirs
for C. difficile, though incubators have been implicated in trans-
mission of vancomycin-resistant Enterococcus from patient to
patient in a published study.38
Question: What is the role for antimicrobial stewardship in the
prevention of C. difficile infection in infants?
Answer: Antimicrobial stewardship has resulted in decreases in
CDI in many populations, and because of its beneficial impact on
other adverse events seen in the NICU, encouraging appropriate
use of antimicrobials in the NICU should be a priority.
Antimicrobial stewardship efforts have been shown to significantly
decrease rates of CDI in adults,39 although data for the neonatal
population are lacking and would be more challenging to interpret
given high colonization rates. Prolonged use of empiric antibiotics
in neonates has been associated with an increased risk
of necrotizing enterocolitis and death40 and invasive candidiasis.41
Therefore, although no specific recommendation can be made
regarding antimicrobial stewardship as a means of prevention of
CDI in the NICU, every NICU should have stewardship processes
in place to ensure appropriate use of antimicrobials.
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